Use of PRRT and osilodrostat for ectopic Cushing syndrome secondary to thymic neuroendocrine neoplasm
Endocrinology, Diabetes & Metabolism Case Reports · 01.04.2026 · 2026 (2)
DOI: 10.1530/edm-25-0138 ↗Kurz gefasst
Fallbericht in der Zeitschrift Endocrinology, Diabetes & Metabolism Case Reports, online erschienen am 28.04.2026. Verfasst von Monica Majumder und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
We present a case of recurrent thymic neuroendocrine neoplasm (NEN) in a 43-year-old male, who developed ectopic Cushing syndrome (CS), 8 years after his initial diagnosis. Due to persistent biochemical hypercortisolism and clinical symptoms of CS, he was trialled on multiple adrenal steroidogenesis inhibitors with surgical resection and radiotherapy. Eventually, he was transitioned to osilodrostat, a new potent adrenal steroidogenesis inhibitor. Following multidisciplinary discussion, he underwent peptide receptor radionuclide therapy (PRRT). After 12 months of therapy, his cortisol levels have normalised. This is a novel case of functional thymic NEN that was biochemically responsive to osilodrostat and PRRT. Osilodrostat predominantly blocks 11-β hydroxylase leading to a reduction in biochemical hypercortisolism and improvement in clinical manifestations. Initial evidence supported its role in the setting of Cushing’s disease. There is growing evidence for its use in the setting of ectopic CS as observed with our case. PRRT continues to have a role in the setting of functional NENs. Learning points
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia.
- Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
- Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia.
- Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
ORCID-Profile: Monica Majumder
Zitieren
APA
Majumder, M., Clarke, S., Bernard, E., & Tsang, V. H. M. (2026). Use of PRRT and osilodrostat for ectopic Cushing syndrome secondary to thymic neuroendocrine neoplasm. Endocrinology, Diabetes & Metabolism Case Reports, 2026(2). https://doi.org/10.1530/edm-25-0138
Vancouver
Majumder M, Clarke S, Bernard E, Tsang VHM. Use of PRRT and osilodrostat for ectopic Cushing syndrome secondary to thymic neuroendocrine neoplasm. Endocrinology, Diabetes & Metabolism Case Reports. 2026;2026(2). doi:10.1530/edm-25-0138
BibTeX
@article{Majumder2026,
author = {Majumder, Monica and Clarke, Stephen and Bernard, Elizabeth and Tsang, Venessa H M},
title = {Use of PRRT and osilodrostat for ectopic Cushing syndrome secondary to thymic neuroendocrine neoplasm},
journal = {Endocrinology, Diabetes & Metabolism Case Reports},
year = {2026},
volume = {2026},
number = {2},
doi = {10.1530/edm-25-0138}
}
EUVIMED